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Zika virus (ZIKV) is the last arbovirosis to arrive to the
American continent, following dengue virus (DENV) in 1990,
West Nile virus (WNV) in 1999 and chikungunya (CHIK) at
2013. At this time, it represents a pandemic at this continent [1].
It was ﬁrst isolated from a rhesus monkey at the Zika forest
near Kampala, Uganda in 1947 and from mosquito Aedes
africanus in 1948 [2]. It is a member of Flaviviridae family,
along with yellow fever virus (YFV), DENV, WNV and
Japanese encephalitis virus [1,3]. The ﬁrst reports of human
infection were in Uganda and Tanzania, in 1952 [4]. Since
then, ZIKV has spread from Africa to Southeast Asia and
Paciﬁc Islands [1,4,5]. The ﬁrst epidemic started in 2007 at
Yap Islands, Micronesia, which was also the ﬁrst detection of
ZIKV outside of Africa and Asia, with an estimate of 73%
population infected and 49 conﬁrmed cases [6]. The second
and largest epidemic was at French Polynesia, reaching 28000
medical attentions which represented about 11% of population
[7] and almost 70% in some islands [8]. Hence it spreads
through the Paciﬁc, where it is still actually circulating in
New Caledonia, Cook Islands, Vanatu, Solomon Islands, Fiji
and Easter Island [7]. It is believed that the last one make the
epidemiological entrance of the virus to the Americas, on
May 2015 in Brazil [8,9].
Today ZIKV has autochthonous transmission in 33 countries
and regions of the American continent [10], where the main
vector is Aedes aegypti (A. aegypti), also carrier of DENV,
YFV and CHIK. In 1947 A. aegypti was eradicated from 18
countries through efforts of Pan-American Health Organization
(PHO) and the use of organophosphate DDT. However, DDT
use was left in the 1960s and the mosquito returned, so it ispresent now [11]. There are reports of six countries (Argentina,
Chile, France, Italy, New Zealand and United States) without
the presence of the vector and local acquisition of the disease,
probably by sexual intercourse [10].
In Peru, A. aegypti reemerged in 1984 at Loreto and spread to
San Martin region and country's central rainforest zone. Towards
2000 the vector was detected in Lima region, at ﬁve districts (La
Victoria, El Agustino, Rimac, San Juan de Lurigancho, Cercado
de Lima) and later on it spread to other 29 districts. By 2011, the
mosquito presence involved 269 districts and 18 regions of
Peruvian territory, where about a third of the total population
lived [12]. Five haplotypes of A. aegypti have been found, which
indicates that genetic variability is not only because of its active
migration but also because of the passive migration by human
activities [13,14]. Also, A. aegypti has expanded its habitat due
to climate change and El Niño phenomenon, both of which
increase temperature and humidity [15].
ZIKV incubation period is estimated between three and seven
days (range 3–14) after host infection [16]. Course tends to bemild,
last days or weeks and it is suspected that individuals acquire
immunity after ﬁrst episode because reinfection has not been
reported yet [17,18]. Clinical symptoms, present in 20% of cases,
consist in onset of fever and pruriginous maculopapular rash,
arthralgia and/or non-purulent conjunctivitis. Common manifes-
tations are nonspeciﬁc including fever, malaise, headache and
joint pain associated to rash [17–19]. There are neither reports of
hemorrhagic complications, nor synergy or increased severity
when there is coinfection with DENV or CHIK [20,21].
Infection is associated with neurological complications, be-
ing the main and most alarming Guillain–Barre´ syndrome
(GBS). French Polynesia epidemic showed an increase of GBS
cases, which was lately associated in a case–control study of 42ility of Hainan Medical University.
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incidence of GBS while ZIKV was circulating [10]. Also, in
Brazil, within the 2014–2015 period, the incidence of
microcephaly in newborns increased 20 times [1], reporting
initially 141 suspected cases in Pernambuco, followed by
other northeastern states (Paramaiba, Rio Grande do Norte),
alongside spontaneous abortions and miscarriages [23]. First
months of pregnancy of the newborns match the highest
incidence periods of ZIKV at northeastern Brazil and there
was not family history of either genetic diseases or positive
tests for other infections [24].
Causal association was carried out by Instituto Evadro Cha-
gas through isolation of ZIKV from brain tissue and detection of
virus in cerebrospinal ﬂuid (CSF) and, brain tissue and frag-
ments of viscera (heart, lungs, liver, spleen, kidney) of a
newborn that died shortly after birth [23,24]. In addition, ZIKV
IgM was found in CSF of 12 newborns with microcephaly
and negative to TORCH test (Toxoplasma gondii, other
agents, rubella, cytomegalovirus and herpes simplex virus
types 1 and 2), DENV and CHIK [24]. Two cases reported
ZIKV in amniotic ﬂuid and microcephaly by ultrasound [25].
Centre for Disease Control and Prevention (CDC) conﬁrmed
the presence of virus in cerebral tissue and placenta using
polymerase chain reaction (PCR) and immunohistochemistry
methods [26]. Besides neurological damage, there is evidence
of ocular compromise as macular atrophy, and both macular
and perimacular injuries with optical nerve atrophy [24]. Brazil
has reported 739 microcephaly cases and other fetal
malformations until 21st November, 2015 [9].
One of the major difﬁculties is the lack of commercial
serological and molecular diagnostic tests. Those now available
are limited to reference laboratories and cannot fulﬁll public
health demand. It is necessary to develop fast tests (immuno-
chromatography), and serologic (ELISA IgM, IgG) and molec-
ular methods for early diagnosis of ZIKV infection, according to
circumstances of involved countries, most of which are low or
middle income countries [1,24]. Use of the diagnosis tests should
be prioritized for susceptible population as pregnant women and
individuals with chronic or autoimmune diseases [24]. On the
other hand, these tests will contribute to a better case manage,
preventing and treating the complications according etiology [1].
ZIKV is not well known comparing to other virus. However,
due to its neurotropism it causes microcephaly and is associated
with GBS. Presence of A. aegypti in many regions of Peru makes
it easier to spread and could be present in population, not being
detected well timed because there is a lack of diagnosis methods.
It is important to take appropriate control measures and lower
case numbers for the control of mosquito. A quick, effective and
combined response is needed by the World Health Organization
(WHO) Member States through ﬁnancial aid and assistance.
Also, a vaccine for this virus should be developed to prevent not
only the infection but also its main complications.Conﬂict of interest statement
We declare that we have no conﬂict of interest.References
[1] Fauci AS, Morens DM. Zika virus in the Americas–yet another
arbovirus threat. N Engl J Med 2016; 374(7): 601-604.[2] Dick GW, Kitchen SF, Haddow AJ. Zika virus I. Isolations and
serological speciﬁcity. Trans R Soc Trop Med Hyg 1952; 46(5):
509-520.
[3] Lucey DR, Gostin LO. The emerging Zika pandemic: enhancing
preparedness. JAMA 2016; 315(9): 865-866.
[4] Dick GW. Zika virus. II. Pathogenicity and physical properties.
Trans R Soc Trop Med Hyg 1952; 46(5): 521-534.
[5] Hennessey M, Fischer M, Staples JE. Zika virus spreads to new
areas – region of the Americas, May 2015–January 2016. MMWR
Morb Mortal Wkly Rep 2016; 65(3): 55-58.
[6] Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL,
Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated
States of Micronesia. N Engl J Med 2009; 360(24): 2536-2543.
[7] Musso D, Nilles EJ, Cao-Lormeau VM. Rapid spread of emerging
Zika virus in the Paciﬁc area. Clin Microbiol Infect 2014; 20(10):
O595-O596.
[8] Dyer O. Zika virus spreads across Americas as concerns mount
over birth defects. BMJ 2015; 351: h6983.
[9] Gatherer D, Kohl A. Zika virus: a previously slow pandemic
spreads rapidly through the Americas. J Gen Virol 2015; 97(2):
269-273.
[10] Pan American Health Organization. Zika virus infection. [Online]
Available from: http://www.paho.org/hq/index.php?option=com_
content&view=article&id=11585&Itemid=41688&lan=es
[Accessed on 10th March, 2016].
[11] Dick OB, San Martı´n JL, Montoya RH, del Diego J, Zambrano B,
Dayan GH. The history of dengue outbreaks in the Americas. Am J
Trop Med Hyg 2012; 87(4): 584-593.
[12] Peru, Ministerio de Salud. Aprendiendo de la experiencia: lec-
ciones aprendidas para la preparacion y respuesta en el control
vectorial ante brotes de dengue en el Peru. Lima: MINSA; 2011.
[13] Yanez P, Mamani E, Valle J, Garcı´a MP, Leo´n W, Villaseca P,
et al. Variabilidad genetica del Aedes aegypti determinada
mediante el analisis del gen mitocondrial ND4 en once areas
endemicas para dengue en el Peru. Rev Peru Med Exp Salud
Publica 2013; 30(2): 246-250.
[14] Leiva N, Ca´ceres O. Variabilidad genetica de Aedes aegypti en
algunas areas del Peru usando Single Stranded Conformational
Polymorphism (SSCP). Rev Peru Med Exp Salud Publica 2004;
21(3): 157-166.
[15] Paz S, Semenza JC. El Niño and climate change–contributing
factors in the dispersal of Zika virus in the Americas? Lancet 2016;
387(10020): 745.
[16] Rudolph KE, Lessler J, Moloney RM, Kmush B, Cummings DA.
Incubation periods of mosquito-borne viral infections: a systematic
review. Am J Trop Med Hyg 2014; 90(5): 882-891.
[17] Simpson DI. Zika virus infection in man. Trans R Soc Trop Med
Hyg 1964; 58: 335-338.
[18] Centers for Disease Control and Prevention. Zika virus: for health
care providers: clinical evaluation & disease. [Online] Available
from: http://www.cdc.gov/zika/hc-providers/clinicalevaluation.
html [Accessed on 13th January, 2016].
[19] Filipe AR, Martins CM, Rocha H. Laboratory infection with Zika
virus after vaccination against yellow fever. Arch Gesamte Virus-
forsch 1973; 43(4): 315-319.
[20] Villamil-Go´mez WE, Gonza´lez-Camargo O, Rodriguez-Ayubi J,
Zapata-Serpa D, Rodriguez-Morales AJ. Dengue, chikungunya and
Zika co-infection in a patient from Colombia. J Infect Public Health
2016; 9(5): 684-686. http://dx.doi.org/10.1016/j.jiph.2015.12.002.
[21] Dupont-Rouzeyro M, O'Connor O, Calvez E, Daure`s M, John M,
Grangeon JP, et al. Co-infection with Zika and dengue viruses in 2
patients, New Caledonia, 2014. Emerg Infect Dis 2015; 21(2): 381-
382.
[22] Cao-Lormeau VM, Blake A, Mons S, Laste`re S, Roche C,
Vanhomwegen J, et al. Guillain-Barre´ syndrome outbreak associ-
ated with Zika virus infection in French Polynesia: a case-control
study. Lancet 2016; 387(10027): 1531-1539.
[23] Kindhauser MK, Allen T, Frank V, Santhana RS, Dye C. Zika: the
origin and spread of a mosquito-borne virus. Bull World Health
Organ 2016, BLT.16.171082. http://dx.doi.org/10.2471/BLT.16.
171082.
S. Levy-Blitchtein, J. del Valle-Mendoza/Asian Paciﬁc Journal of Tropical Medicine 2016; 9(10): 1019–1021 1021[24] de Oliveira CS, da Costa Vasconcelos PF. Microcephaly and Zika
virus. J Pediatr (Rio J) 2016; 92(2): 103-105.
[25] de Paula Freitas B, de Oliveira Dias JR, Prazeres J,
Sacramento GA, Ko AI, Maia M, et al. Ocular ﬁndings in infants
with microcephaly associated with presumed Zika virus congenital
infection in Salvador, Brazil. JAMA Ophthalmol 2016; 134(5):
529-535. http://dx.doi.org/10.1001/jamaophthalmol.2016.0267.[26] Martines RB, Bhatnagar J, Keating MK, Silva-Flannery L,
Muehlenbachs A, Gary J, et al. Notes from the ﬁeld: evidence of
Zika virus infection in brain and placental tissues from two
congenitally infected newborns and two fetal losses–Brazil, 2015.
MMWR Morb Mortal Wkly Rep 2016; 65(6): 159-160.
